Publikation:
Improving environmental protection in EU pharmaceutical legislation

dc.contributor.authorGildemeister, Daniela
dc.contributor.authorBuck, Annika
dc.contributor.authorHein, Arne
dc.contributor.authorRönnefahrt, Ines
dc.contributor.authorEbert, Ina
dc.contributor.authorDebiak, Malgorzata
dc.date.issued2022
dc.description.abstractIn preparation of the revision of Directive 2001/83/ EC and Regulation (EC) No 726/2004, the German Environment Agency (UBA) proposes legal changes to reduce pharmaceutical residues in the environment. The proposals are based on UBA's experiences as competent authority for the environmental risk assessment (ERA) of pharmaceuticals. Our overall aim is to ensure a comprehensive risk management system without compromising availability of medicines for patients. In this context we consider the recent EU strategy on pharmaceuticals and initiatives in connection with EU`s Green Deal particularly the Zero Pollution Ambition and the one substance one assessment approach. Quelle: www.umweltbundesamt.deen
dc.description.abstractIn preparation of the revision of Directive 2001/83/ EC and Regulation (EC) No 726/2004, the German Environment Agency (⁠UBA⁠) proposes legal changes to reduce pharmaceutical residues in the environment. The proposals are based on UBA’s experiences as competent authority for the environmental risk assessment (ERA) of pharmaceuticals. Our overall aim is to ensure a comprehensive risk management system without compromising availability of medicines for patients. In this context we consider the recent EU strategy on pharmaceuticals and initiatives in connection with EU`s Green Deal particularly the Zero Pollution Ambition and the one substance one assessment approach.en
dc.description.abstractIn preparation of the revision of Directive 2001/83/ EC and Regulation (EC) No 726/2004, the German Environment Agency (UBA) proposes legal changes to reduce pharmaceutical residues in the environment. The proposals are based on UBA’s experiences as competent authority for the environmental risk assessment (ERA) of pharmaceuticals. Our overall aim is to ensure a comprehensive risk management system without compromising availability of medicines for patients. In this context we consider the recent EU strategy on pharmaceuticals and initiatives in connection with EU`s Green Deal particularly the Zero Pollution Ambition and the one substance one assessment approach.en
dc.format.extent23
dc.format.mediumonline resource
dc.identifier.doihttps://doi.org/10.60810/openumwelt-3797
dc.identifier.urihttps://openumwelt.de/handle/123456789/2585
dc.language.isoeng
dc.publisherUmweltbundesamt
dc.relation.ispartofseriesScientific Opinion Paper
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.source.urihttp://www.umweltbundesamt.de/sites/default/files/medien/1410/publikationen/2022-10-26_sop_environmental-protection-eu-pharmaceutical-legislation_bf.pdf
dc.subjectUmweltrisikobewertung
dc.subjectpharmaceuticals
dc.subjectenvironmental risk assessment
dc.subject.ubaThemeChemicals
dc.subject.ubaThemeChemikalien
dc.subject.ubaThemeGesundheit
dc.subject.ubaThemeNachhaltigkeit | Strategien | Internationales
dc.subject.ubaThemeHealth
dc.subject.ubaThemeSustainability | Strategies | International matters
dc.titleImproving environmental protection in EU pharmaceutical legislationen
dc.typeMonographie
dspace.entity.typePublication
local.audiencePublic authorities
local.bibliographicCitation.publisherPlaceDessau-Roßlau
local.collectionScientific Opinion Paper
local.ingest.needsManualMetadataChecktrue
local.subtitleRecommendations for reducing adverse environmental impacts from human pharmaceuticalsen

Dateien

Originalbündel

Gerade angezeigt 1 - 1 von 1
Vorschaubild
Name:
2022-10-26_sop_environmental-protection-eu-pharmaceutical-legislation_bf.pdf
Größe:
1011.72 KB
Format:
Adobe Portable Document Format
Beschreibung:
2022-10-26_sop_environmental-protection-eu-pharmaceutical-legislation_bf.pdf, downloaded 2024-06-16T13:10:16.225655